https://www.selleckchem.com/products/turi.html
Two patients developed a low-titre inhibitor against rpFVIII, neither experienced any complications. Discussion In our real world experience, susoctocog-alfa was proven to be an effective and safe therapeutic option for patients with AHA, also at a lower than recommended dosage. In our report, the appearance of low-titre inhibitors.Background Platelet transfusions are necessary to prevent and treat haemorrhages in thrombocytopenic patients or those with severe platelet dysfunction. In Latin American countries, including Argentina, blood su
Like
Comment
Share
